Eplerenone is a blocker of aldosterone binding at the mineralocorticoid receptor. Eplerenone binds to the mineralocorticoid receptor and blocks the binding of aldosterone, a component of the renin-angiotensin-aldosterone system (RAAS). This drug comes as an odourless, white to off-white crystalline powder. Healthcare providers use the drug Eplereone for improving survival of stable patients with LV systolic dysfunction (LVEF ≤40%) and congestive heart failure (CHF) after an acute myocardial infarction and for Hypertension, alone or in combination with other antihypertensive agents.
Eplerenone tablets come two different strengths:
Dosage and Administration
In case of Congestive Heart Failure Post-Myocardial Infarction, the general recommended dosage of Eplerenone initiates treatment at 25 mg once daily and titrates to the recommended dose of 50 mg once daily, preferably within 4 weeks as tolerated by the patient. The recommended starting daily dose of Eplerenone 50 mg should be administered once daily. The full therapeutic effect of Eplerenone is apparent within 4 weeks. For patients with an inadequate blood pressure response to 50 mg once daily, the dosage of Eplerenone should be increased to 50 mg twice daily. Healthcare professionals recommend not administering higher doses of Eplerenone because they have no greater effect on blood pressure than 100 mg and are associated with an increased risk of hyperkalemia.
Side Effects
Every generic medicine has some side effects such as:
- In the case of Eplerenone administration in Congestive Heart Failure Post-Myocardial Infarction, the adverse reactions can be hyperkalemia, MI, and abnormal renal function.
- In the case of Hypertension, the administration of Eplerenone tablets can lead to side effects including headache, dizziness, angina pectoris/MI, and increased GGT.
Warnings and Precautions
- Measure serum potassium before initiating Eplerenone therapy, within the first week and at one month after the start of treatment or dose adjustment. Assess serum potassium periodically after that.
- Post-MI CHF patients receiving a moderate CYP3A inhibitor (e.g., erythromycin, saquinavir, verapamil, and fluconazole) do not exceed 25 mg once daily.
- In patients with Hypertension receiving a moderate CYP3A inhibitor, initiate at 25 mg once daily. For inadequate blood pressure response, dosing may be increased to 25 mg twice daily.
- One should monitor or evaluate patients for the development of hyperkalemia until the established effect of Eplerenone.
- Before administration of this medicine, one should tell the doctor about the patient's medical history.
- One should consult the doctor about planning to become pregnant as the medicine may harm the fetus.
- It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Cost of Eplerenone in India The Eplerenone cost is reasonable in India, with a large number of pharmaceutical generic medicine suppliers. Ikris Pharma Network is one of the licensed pharmaceutical suppliers, supplying quality drugs globally for more than 7 years.
